Tag

Selloff

All articles tagged with #selloff

Tech Stocks Hit Worst Week Since April Amid Rising Volatility

Originally Published 2 months ago — by MarketWatch

Featured image for Tech Stocks Hit Worst Week Since April Amid Rising Volatility
Source: MarketWatch

Tech stocks experienced their worst weekly decline since April, dropping 4.2% amid concerns over high valuations, despite strong recent earnings and a healthy overall market backdrop. The selloff, driven by profit-taking and valuation concerns, is seen by analysts as a necessary correction that could support future stability.

Market Experts Warn of Imminent Stock and Crypto Decline

Originally Published 2 months ago — by Bloomberg

Featured image for Market Experts Warn of Imminent Stock and Crypto Decline
Source: Bloomberg

US stocks experienced their biggest decline in a month, sparking debate among investors about the potential depth of a market correction amid concerns over high valuations, narrow leadership driven by tech giants, and economic uncertainties, with some analysts suggesting a possible move towards the 6,400-6,500 level for the S&P 500.

Gold Prices Drop Amid Market Uncertainty

Originally Published 2 months ago — by Barron's

Featured image for Gold Prices Drop Amid Market Uncertainty
Source: Barron's

Gold prices experienced a significant decline, with a 5.7% drop marking its largest in over 12 years, driven by profit-taking after a strong rally despite declining bond yields. While some see the pullback as a correction, gold remains on track for its best year since 1979, supported by central bank buying and expectations of lower interest rates, though traders anticipate continued volatility.

Bitcoin Declines Amid JPMorgan's Crypto Natives Critique

Originally Published 2 months ago — by Decrypt

Featured image for Bitcoin Declines Amid JPMorgan's Crypto Natives Critique
Source: Decrypt

Bitcoin and major cryptocurrencies experienced a significant decline, with Bitcoin hitting a 4-month low, driven largely by sell pressure from crypto-native investors rather than institutions, according to JPMorgan. Despite the selloff, institutional inflows into ETFs remain steady, and long-term outlooks remain optimistic, with upcoming cycles and institutional support expected to stabilize the market.

Market Outlook: Experts Warn of Further Stock Declines Amid Economic Uncertainty

Originally Published 5 months ago — by MarketWatch

Featured image for Market Outlook: Experts Warn of Further Stock Declines Amid Economic Uncertainty
Source: MarketWatch

U.S. stocks have declined since August, with warnings from strategists about a potential deeper correction of 7-15% by mid-October, driven by high valuations, seasonal weakness, overbought conditions, and rising market volatility, though the long-term bull market may still be intact.

Novo Nordisk Faces Stock Drop Amid Market Challenges and Competition

Originally Published 5 months ago — by Seeking Alpha

Featured image for Novo Nordisk Faces Stock Drop Amid Market Challenges and Competition
Source: Seeking Alpha

The author downgrades Novo Nordisk from Strong Buy to Buy due to recent guidance cuts and competitive pressures, but remains optimistic about its long-term prospects given its manufacturing scale and pipeline. The stock has experienced a sell-off similar to 2016, but the company’s history of navigating growth slowdowns suggests patience is needed for a potential recovery, making it a suitable long-term investment for those comfortable with volatility.

FET Faces Uncertainty Amid Slowing Rally and Market Pressure

Originally Published 1 year ago — by AMBCrypto News

Featured image for FET Faces Uncertainty Amid Slowing Rally and Market Pressure
Source: AMBCrypto News

FET, part of the Artificial Superintelligence Alliance, has been on a bullish trend but faces challenges as it approaches resistance levels within a symmetrical triangle pattern. Analyst Crypto Leo notes that breaking these levels is crucial for FET to continue its rally, potentially reaching $3.50. However, significant sell-offs and liquidation of long positions are creating downward pressure, delaying the rally. Despite this, a 10.20% increase in Open Interest suggests a lingering bullish sentiment, though FET's breakout remains uncertain.

"Gilead's Stock Plummets as Lung Cancer Treatment Trial Disappoints"

Originally Published 2 years ago — by MarketWatch

Featured image for "Gilead's Stock Plummets as Lung Cancer Treatment Trial Disappoints"
Source: MarketWatch

Gilead Sciences' stock plunges over 10% in premarket trading after disappointing trial results for its lung cancer treatment, Trodelvy, failing to meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer. The company plans to discuss the results with regulators, expressing continued confidence in Trodelvy's potential in metastatic NSCLC despite the setback.